Facebook
Twitter
LinkedIn
Forward
This webinar re-playing the popular session from the Obesity Medicine Conference 2021 provides a brief overview of FDA-approved anti-obesity medications (AOM’s).
|
The global COVID-19 pandemic has turned our patient’s lives and routines upside down.
|
Patients and Primary Care Clinicians face numerous difficulties in providing effective, affordable weight loss and maintenance programs.
|
During this webinar, Dr.
|
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
|
This presentation discusses the particular administrative needs and challenges related to treating obesity.
|
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
In June of 2023 the AASLD updated the nomenclature for NAFLD to Metabolic dysfunction-Associated Steatotic Liver Disease(MASLD).
|
Printed Syllabus including lecture slides and case work
|
Printed Syllabus including lecture slides and case work
|